Merck
GSK shingles vaccine on form
December 19, 2014Sales and Marketing GSK, HZ/su, Merck, Vaccine, Zostavax, shingles
GlaxoSmithKline will be celebrating following the successful Phase III study of its shingles vaccine HZ/su that has met its primary …
Big pharma spent $112 billion on R&D in 2013
December 17, 2014Research and Development, Sales and Marketing Merck, Pfizer, R&D, Roche, data, global data, research
The top 30 pharma companies spent a combined total of $112 billion on research and development last year. Calculated to …
GSK Ebola vaccine gets EU support
December 17, 2014Research and Development, Sales and Marketing EC, EU, Ebola, Europe, GSK, Merck, Takeda, Vaccine, WHO, johnson
A newly-formed European consortium is to help advance the development of GlaxoSmithKline’s promising Ebola vaccine. The consortium is backed by …
Gavi pledges $300 million for Ebola vaccines
December 12, 2014Manufacturing and Production, Sales and Marketing GAVI, GSK, GlaxoSmithKline, J&J, JJ, Merck, Vaccine, WHO, newlink
The global vaccines alliance Gavi has committed to buying Ebola vaccines as soon as the World Health Organization recommends one …
Antibiotic resistance could kill 10 million a year
December 11, 2014Research and Development, Sales and Marketing Antibiotics, Cancer, KPMG, Merck, david cameron, rand
Antibiotic-resistant bacteria will kill an extra 10 million people a year by 2050 if the problem is not tackled soon, …
Updated: Merck buys antibiotics specialist Cubist
December 8, 2014Sales and Marketing Antibiotics, Merck, Novartis, cubicin, cubist, eumer
Merck has purchased US antibiotics maker Cubist in a deal valued at $9.5 billion. The acquisition values Cubist at around …
Merck sells manufacturing facility to Sanofi
December 5, 2014Manufacturing and Production, Sales and Marketing Merck, Merial, Puerto Rico, Sanofi, manufacturing
Sanofi’s animal health unit Merial is acquiring Merck’s manufacturing facility in Barceloneta, Puerto Rico. The proposed transaction requires the nod …
Merck Ebola vaccine shows promise
December 4, 2014Research and Development, Sales and Marketing Ebola, Merck, VSV-ZEBOV, WHO, hug, newlink genetics
Merck and NewLink Genetics’ experimental Ebola vaccine has shown no major side effects in its first trial according to the …
Merck revenue falls
October 28, 2014Manufacturing and Production, Sales and Marketing Frazier, Merck, Q3, Victrelis, hep C, sovaldi
Merck has posted a set of disappointing financials for the latest quarter as it cuts cost across its business to …
BMS sues Merck over new melanoma drug
September 8, 2014Research and Development, Sales and Marketing BMS, FDA, Merck, PD-1 inhibitors, Yervoy, keytruda
Things are getting ugly between Bristol-Myers Squibb and Merck as the former company began legal proceedings against the latter over …
Merck surprise winner in PD-1 race
September 5, 2014Medical Communications, Research and Development, Sales and Marketing Cancer, Merck, melanoma, pd-1
Merck has become the first company to bring a new class of cancer drug to the US market after the …
US rivals Pfizer and Merck team up for lung cancer
August 27, 2014Medical Communications, Research and Development, Sales and Marketing Merck, NSCLC, Roche, Xalkori, melanoma, pembrolizumab
The two biggest rival US pharma firms have joined forces to help develop a new combination treatment for certain non-small …
Merck and Advaxis team up on immuno-oncology
August 26, 2014Manufacturing and Production, Medical Communications, Research and Development ASCO, Merck, immunology, pd-1, pembrolizumab
Advaxis and Merck have signed a research deal to investigational Merck’s PD-1 inhibitor pembrolizumab in combination with Advaxis’ listeria-based cancer …
PD-1 cancer race heats up as Merck takes lead
July 2, 2014Research and Development, Sales and Marketing ASCO, Cancer, Merck, melanoma, mk3475, oncology, pembrolizumab
Merck’s oncology drug pembrolizumab has taken a big step towards becoming Europe’s first PD-1 cancer treatment as the EMA accepts …
Merck buys Idenix
June 10, 2014Manufacturing and Production, Sales and Marketing HCV, IDX21437, IDX21459, Merck, hep C, idenix
Merck is to improve its pipeline of hepatitis C virus (HCV) treatments by splashing out $3.85 billion on biopharma firm …
Latest content
Scots neonatal innovations target hearing loss and earlier care
Agentis Health Group acquires Clinical Pharmacist Solutions
